ReviewCurrent hematologic malignancy reports2011
Late effects of childhood leukemia therapy.
Review in Current hematologic malignancy reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Article
- A systematic review of long-term cardiotoxic effects of treatment in survivors of childhood acute lymphoblastic leukemia.Molecular and cellular pediatrics · 2025Review
- Premature thymic functional senescence is a hallmark of childhood acute lymphoblastic leukemia survivorship.Blood cancer journal · 2024Article
- Article
- A gut instinct for childhood leukemia prevention: microbiome-targeting recommendations aimed at parents and caregivers.Frontiers in public health · 2024Review
- Case Report: Blinatumomab as upfront consolidation and maintenance therapy in a pediatric patient with high-risk B-cell acute lymphoblastic leukemia.Frontiers in oncology · 2023Article
- Apolipoproteins-New Biomarkers of Overweight and Obesity among Childhood Acute Lymphoblastic Leukemia Survivors?International journal of molecular sciences · 2022Article
- Article
- Article
- Increased Levels of Adipocyte and Epidermal Fatty Acid-Binding Proteins in Acute Lymphoblastic Leukemia Survivors.Journal of clinical medicine · 2021Article
- Cardiac autonomic dysfunction in survivors of childhood acute lymphoblastic leukemia: The St. Jude Lifetime Cohort Study.Pediatric blood & cancer · 2020Article
- Long-Term Risk of Hospitalization Among Five-Year Survivors of Childhood Leukemia in the Nordic Countries.Journal of the National Cancer Institute · 2019Article
- Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia SurvivorsTurkish journal of haematology : official journal of Turkish Society of Haematology · 2019Review
- Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.PLoS genetics · 2018Article
- Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.BMC cancer · 2018Article
- CD47-ligation induced cell death in T-acute lymphoblastic leukemia.Cell death & disease · 2018Article
- Assessment of the chemosensitizing activity of TAT-RasGAP317-326 in childhood cancers.PloS one · 2015Article
- Headache types, related morbidity, and quality of life in survivors of childhood acute lymphoblastic leukemia: a prospective cross sectional study.European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · 2014Article
- Health promotion for adolescent childhood leukemia survivors: building on prevention science and ehealth.Pediatric blood & cancer · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As survival rates for children treated for childhood cancers become significantly better, the focus is increasingly on determining the late effects of treatments and the best ways to monitor for them and prevent their occurrence. This review focuses on recent literature discussing the late effects of treatment in patients treated for acute myeloid leukemia and acute lymphoblastic leukemia during childhood. The late effects of therapy for childhood leukemia include secondary malignancy, cardiotoxicity, obesity, endocrine abnormalities, reproductive changes, neurocognitive deficits, and psychosocial effects. As clinicians have become more aware of the late effects of therapy, treatment regimens have been changed to decrease late effects, but patients still require long-term follow-up for their prevention and treatment.
Indexed as
Identifiers
21695425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.